ID

27942

Beschrijving

Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.; ODM derived from: https://clinicaltrials.gov/show/NCT00632125

Link

https://clinicaltrials.gov/show/NCT00632125

Trefwoorden

  1. 06-12-17 06-12-17 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

6 december 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Chronic Kidney Disease NCT00632125

Eligibility Chronic Kidney Disease NCT00632125

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
ckd subjects with or without dialysis treatment
Beschrijving

Chronic Kidney Disease | Dialysis

Datatype

boolean

Alias
UMLS CUI [1]
C1561643
UMLS CUI [2]
C0011946
age over 18 years
Beschrijving

Age

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
subjects requiring i.v. esa treatment
Beschrijving

Erythropoiesis-stimulating Agent Intravenous Patient need for

Datatype

boolean

Alias
UMLS CUI [1,1]
C2917382
UMLS CUI [1,2]
C1522726
UMLS CUI [1,3]
C0686904
subjects likely to remain on i.v. esa treatment for 6 months
Beschrijving

ESA Intravenous Remaining Probably

Datatype

boolean

Alias
UMLS CUI [1,1]
C2917382
UMLS CUI [1,2]
C1522726
UMLS CUI [1,3]
C1527428
UMLS CUI [1,4]
C0750492
provision of informed consent -
Beschrijving

Informed Consent

Datatype

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
systemic immunosuppressive medication or any other drugs known to adversely affect the hemoglobin level
Beschrijving

Immunosuppressive Agents Systemic | Pharmaceutical Preparations Adverse effects Hemoglobin level

Datatype

boolean

Alias
UMLS CUI [1,1]
C0021081
UMLS CUI [1,2]
C0205373
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0879626
UMLS CUI [2,3]
C0019029
known primary lack of efficacy (loe), unexplained loss of effect to a recombinant erythropoietin product
Beschrijving

Recombinant Erythropoietin Lack of Efficacy Primary | Recombinant Erythropoietin Loss Effect Unknown

Datatype

boolean

Alias
UMLS CUI [1,1]
C0376541
UMLS CUI [1,2]
C0235828
UMLS CUI [1,3]
C0205225
UMLS CUI [2,1]
C0376541
UMLS CUI [2,2]
C1517945
UMLS CUI [2,3]
C1280500
UMLS CUI [2,4]
C0439673
history of prca or aplastic anemia
Beschrijving

Pure Red-Cell Aplasia | Aplastic Anemia

Datatype

boolean

Alias
UMLS CUI [1]
C0034902
UMLS CUI [2]
C0002874
history of anti-erythropoietin antibodies
Beschrijving

Anti-erythropoietin antibody

Datatype

boolean

Alias
UMLS CUI [1]
C1328371
uncontrolled hypertension
Beschrijving

Uncontrolled hypertension

Datatype

boolean

Alias
UMLS CUI [1]
C1868885
pregnant woman or nursing mother
Beschrijving

Pregnancy | Breast Feeding

Datatype

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
women of childbearing potential do not agree to maintain effective birth control during the study treatment period.
Beschrijving

Childbearing Potential Contraceptive methods Unwilling

Datatype

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C0558080

Similar models

Eligibility Chronic Kidney Disease NCT00632125

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Chronic Kidney Disease | Dialysis
Item
ckd subjects with or without dialysis treatment
boolean
C1561643 (UMLS CUI [1])
C0011946 (UMLS CUI [2])
Age
Item
age over 18 years
boolean
C0001779 (UMLS CUI [1])
Erythropoiesis-stimulating Agent Intravenous Patient need for
Item
subjects requiring i.v. esa treatment
boolean
C2917382 (UMLS CUI [1,1])
C1522726 (UMLS CUI [1,2])
C0686904 (UMLS CUI [1,3])
ESA Intravenous Remaining Probably
Item
subjects likely to remain on i.v. esa treatment for 6 months
boolean
C2917382 (UMLS CUI [1,1])
C1522726 (UMLS CUI [1,2])
C1527428 (UMLS CUI [1,3])
C0750492 (UMLS CUI [1,4])
Informed Consent
Item
provision of informed consent -
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Immunosuppressive Agents Systemic | Pharmaceutical Preparations Adverse effects Hemoglobin level
Item
systemic immunosuppressive medication or any other drugs known to adversely affect the hemoglobin level
boolean
C0021081 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0013227 (UMLS CUI [2,1])
C0879626 (UMLS CUI [2,2])
C0019029 (UMLS CUI [2,3])
Recombinant Erythropoietin Lack of Efficacy Primary | Recombinant Erythropoietin Loss Effect Unknown
Item
known primary lack of efficacy (loe), unexplained loss of effect to a recombinant erythropoietin product
boolean
C0376541 (UMLS CUI [1,1])
C0235828 (UMLS CUI [1,2])
C0205225 (UMLS CUI [1,3])
C0376541 (UMLS CUI [2,1])
C1517945 (UMLS CUI [2,2])
C1280500 (UMLS CUI [2,3])
C0439673 (UMLS CUI [2,4])
Pure Red-Cell Aplasia | Aplastic Anemia
Item
history of prca or aplastic anemia
boolean
C0034902 (UMLS CUI [1])
C0002874 (UMLS CUI [2])
Anti-erythropoietin antibody
Item
history of anti-erythropoietin antibodies
boolean
C1328371 (UMLS CUI [1])
Uncontrolled hypertension
Item
uncontrolled hypertension
boolean
C1868885 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
pregnant woman or nursing mother
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Childbearing Potential Contraceptive methods Unwilling
Item
women of childbearing potential do not agree to maintain effective birth control during the study treatment period.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0558080 (UMLS CUI [1,3])

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial